Pridopidine Phase 3 Study in Huntington's Disease

ClinicalTrials.gov ID: NCT07609108

Public ClinicalTrials.gov record NCT07609108. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 4, 2026, 2:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants With Huntington's Disease (HD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this clinical trial is to learn if pridopidine can slow the clinical decline of Huntington's Disease (HD) in adult participants. It will also inform about the safety of pridopidine. The main questions the study aims to answer are: Does pridopidine slow the overall worsening of HD over 1 year? Does pridopidine slow the worsening of specific aspects of HD over 1 year, namely the clinical progression, the ability to perform daily life activities (functional capacity), the mind's ability to process information (cognition), working of the muscles (motor function), and quality of life? Researchers will compare the drug pridopidine to a placebo (a look-alike substance that contains no drug) to see if pridopidine works better than placebo to treat HD. During the first year of the study, participants will have the same chance to receive either pridopidine or placebo. Participants will: Take 1 pridopidine or placebo capsule twice daily for 12 months. Visit the clinic 6 times within 1 year for checkups and tests. All participants who complete this 1-year placebo-controlled study period will roll over into an additional 2-year study period during which all participants will receive pridopidine treatment, including participants who had received placebo during the first year. During this additional 2-year treatment period participants will visit the clinic a total of 6 times for checkups and tests.

Study identification

NCT ID: NCT07609108
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Prilenia; Industry
Enrollment: 400 participants

Conditions and interventions

Conditions

Huntington Disease

Interventions

Pridopidine Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 23 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 30, 2026
Primary completion: May 31, 2028
Completion: May 31, 2030
Last update posted: Aug 6, 2026

2026 – 2030

United States locations

U.S. sites: 25
U.S. states: 17
U.S. cities: 24

Facility	City	State	ZIP	Site status
The University of Alabama at Birmingham	Birmingham	Alabama	35294	Not yet recruiting
University of California, San Diego	La Jolla	California	92037	Recruiting
UCLA Medical Center	Los Angeles	California	90095	Not yet recruiting
UC Davis Medical Center	Sacramento	California	95817	Not yet recruiting
Georgetown University	Washington D.C.	District of Columbia	20007	Not yet recruiting
University of Miami-U Health Boca Raton	Boca Raton	Florida	33486	Not yet recruiting
University of Florida (Norman Fixel Institute for Neurological Diseases)	Gainesville	Florida	32608	Not yet recruiting
Northwestern University	Chicago	Illinois	60611	Not yet recruiting
Rush University Medical Center	Chicago	Illinois	60612	Not yet recruiting
University of Kansas Medical Center	Kansas City	Kansas	66103	Not yet recruiting
Hereditary Neurological Disease Centre	Wichita	Kansas	67226	Recruiting
Johns Hopkins University	Baltimore	Maryland	60612	Not yet recruiting
Massachusetts General Hospital	Charlestown	Massachusetts	02129	Not yet recruiting
Struthers Parkinson's Center / Health Partners Institute	Golden Valley	Minnesota	55427	Not yet recruiting
Columbia University	New York	New York	10032	Not yet recruiting
Duke University	Durham	North Carolina	27705	Not yet recruiting
University of Cincinnati	Cincinnati	Ohio	45219	Not yet recruiting
Cleveland Clinic	Cleveland	Ohio	44195	Not yet recruiting
The Ohio State University	Columbus	Ohio	43221	Not yet recruiting
Oregon Health and Science University (OHSU)	Portland	Oregon	97239	Not yet recruiting
Vanderbilt University Medical Center	Nashville	Tennessee	37212	Not yet recruiting
UT Health, Houston, McGovern Medical School	Houston	Texas	77030	Not yet recruiting
University of Vermont Medical Center	Burlington	Vermont	05401	Not yet recruiting
EvergreenHealth Research Department	Kirkland	Washington	98034	Not yet recruiting
University of Washington	Seattle	Washington	98195	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07609108, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 6, 2026 · Synced Sep 4, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07609108 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →